NEW YORK (GenomeWeb News) – Agilent Technologies and Integrated DNA Technologies today announced a co-marketing agreement for qPCR products.
The agreement covers Agilent's Mx3005P qPCR system and Brilliant qPCR reagents and IDT's PrimeTime qPCR assays.
Terms of the deal were not disclosed.
In a statement, Scott O'Brien, product line manager for Agilent's genomic division, said, "The partnership provides the benefit of performing 5' nuclease probe assays with qPCR reagents that have been extensively tested against competitor reagents and assays."
Coupling PrimeTime qPCR assays with the Brilliant master mix will enable researchers to expand the scope of their research, the two firms said in a joint statement, and added that the combination "will provide an excellent tool for validating discoveries resulting from next-generation sequencing and copy number variation studies."